Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine versus midazolam in adolescents with treatment-resistant depression and/or imminent suicide risk
ChiCTR2200055753Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine and midazolam in major depressive disorder (MDD) and treatment-resistant depression (TRD) (4 arms), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoints: Montgomery-Asberg Depression Rating Scale at Day 84 and Children's Depression Rating Scale-Revised at Day 84. Started Jan 2022; status: recruiting.
02
Drugs
esketaminemidazolam
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ChiCTR2200055753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055753.